
Active Biomarkers
Active Biomarkers offers its expertise for the evaluation of therapies in the detection & quantification of soluble Biomarkers & cell-based assays.
Immunoassays, Flow cytometry, ELISpot, Immunogenicity
The largest immuno-assay platform offer in Europe (MSD, Ella, Luminex, Simoa HD-1, Simoa SP-X, VIDAS, Gyros).
Monitoring the immune response in a regulatory compliant setting is our expertise at Active Biomarkers. We support preclinical and clinical studies to evaluate the safety and efficacy of monoclonal antibodies (mAbs), immune-checkpoint inhibitors, vaccines, Antibody Drug Conjugates (ADCs), Chimeric Antigen Receptor T cells (CAR-T cells) and several other candidate immunotherapies.
- antibodies
- cellular immunotherapy
- immunomodulators
- biomarkers
- hematology
- infectiology
- immunology
- oncology
- Neurological diseases
Expertise
- Functional effects
- ADCC, ADCP & CDC
- Pharmacology & Biological activity
- PK/PD bioavailability
- Mode of Action
- Therapeutic efficacy
- Safety
- Immunogenicity
- Mechanism/Function
- Mechanism of action
- Safety
- PK/PD features
- Indication Identification
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- Research exploratory Companion biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Phase I
- Phase II
- Phase III
- Phase IV
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Safety
- PK/PD features
- Surrogate markers
- Disease progression monitoring
- Post-Market Surveillance
- Treatment efficacy
- Treatment monitoring
- Toxicity
Category
- Service
Contact
- Magali Roche
Sales & Marketing Director - 321 Avenue Jean Jaurès 69007 Lyon
- +33 (0)4 37 70 87 00
- magali.roche@active-biomarkers.com
- https://www.active-biomarkers.com